Key takeaways
- A side-effect profile has to be measured: many people, a comparison group and systematic monitoring. Approved medicines have one; most research peptides do not.
- The US label for semaglutide (Wegovy) lists gastrointestinal effects as the most common, plus warnings including pancreatitis, gallbladder disease and a boxed warning based on rodent thyroid tumours.
- For BPC-157, FDA staff found five small, short human studies and three spontaneous adverse-event reports. One reaction came back when the product was restarted. FDA judged it “likely due to the drug product”, which also contained TB-500, and said it could not assess whether BPC-157 played a role.
- For TB-500 the FDA found no human exposure data at all. Published human trials of thymosin β4 used the full protein, mostly as eye drops or skin gel, plus two small intravenous studies in healthy volunteers and a 2025 trial of a recombinant form in 96 people after a heart attack; none tested TB-500.
- “No side effects reported” in a small study means uncommon effects were not ruled out.
01How are peptide side effects measured?
“What are the side effects?” has a real answer only when someone has measured them.
Measuring side effects takes three things: enough people to see uncommon events, a comparison group to separate the substance from background noise, and monitoring that looks for problems on a schedule. Approved medicines go through this before approval and keep being monitored after it. Most research peptides have had none of it in people.
So this page answers in two parts. First, what approved peptide medicines document. Then, compound by compound, what exists for research peptides, including where the answer is “nothing.” An empty cell is not a clean result; it is missing data. See are peptides safe for why small studies cannot rule out uncommon harms.
02What side effects do approved peptide medicines list? The GLP-1 class
GLP-1 receptor agonists are peptide medicines tested in large controlled trials. Semaglutide and tirzepatide are prescription medicines approved after large controlled trials (STEP 1, 68 weeks; SURMOUNT-1, 72 weeks). Their labels list what those trials found.
The US label for Wegovy (semaglutide), revised June 2026, reports that the most common adverse reactions (incidence of 5% or more) are led by gastrointestinal effects such as nausea, diarrhea and vomiting. It also lists:
- A boxed warning: semaglutide causes thyroid C-cell tumours in rodents; whether it does so in humans is unknown.
- Warnings for acute pancreatitis, acute gallbladder disease, low blood sugar, acute kidney injury from fluid loss, severe gastrointestinal reactions and hypersensitivity reactions.
- Warnings for diabetic retinopathy complications in people with type 2 diabetes, heart rate increase, and pulmonary aspiration during general anaesthesia or deep sedation.
Retatrutide is investigational and not approved anywhere. In its phase 2 trial (n=338, 48 weeks) the most common adverse events were gastrointestinal and dose-related, and heart rate rose, peaking at 24 weeks.
These profiles describe the products tested in those trials and, for the approved medicines, used as labelled. They say nothing about vials sold outside the medical system, which have been found to contain the wrong drug at the wrong strength. See contamination and mislabeling.
03What side effects have been reported for research peptides?
For most research peptides, human adverse-event data barely exist. Only compounds whose human evidence we have verified against primary sources are listed. Tiers follow our evidence grades.
| Compound | Human data | What has been reported | Evidence tier |
|---|---|---|---|
| BPC-157 | Five small, short studies (FDA count, 2026). As of November 2026, none of the human studies registered on ClinicalTrials.gov has posted results. | FDA: no serious adverse events “appear to have been reported,” but the authors gave limited safety information. FDA’s summary of two meeting abstracts on healthy volunteers who received it rectally lists headache and flatulence as the most frequently reported adverse events. Three FDA adverse-event reports to December 2025, all with injected products: redness and swelling at the injection site in a person also using injected thymosin; shortness of breath leading to an emergency visit; and skin and gum darkening that returned when a product containing BPC-157 and TB-500 was restarted. FDA judged that last reaction “likely due to the drug product” but, because the product contained two peptides, could not assess whether BPC-157 played a role. Of all three reports, FDA wrote that “it is unclear whether these AEs were attributable to BPC-157.” | Very limited / early human (T2) |
| TB-500 (usually the 7-amino-acid fragment) | No controlled study. FDA “has not identified any human exposure data” (page current April 2026). A 2026 report describes three patients given TB-500 and BPC-157 together with other agents, without a control group. A randomised phase 1/2 trial of the fragment was registered in 2026 and has not reported. | The 2026 report recorded no adverse events; with several agents and no control group, it cannot show anything about TB-500 itself. FDA says it lacks information on “whether it would cause harm if administered to humans.” | No controlled human data |
| Thymosin β4 (full 43-amino-acid protein) | Controlled trials of eye drops (among them phase 2, n=72; phase 3, n=18) and a skin gel, two randomised intravenous phase 1 studies in healthy volunteers (n=40 and n=84), and a randomised trial of a recombinant form in 96 people after a heart attack (2025). | The phase 2 eye-drop trial reported no adverse events; the phase 3 trial reported no significant adverse effects. In the two intravenous studies, adverse events were mild or moderate and none was serious; both were small and short. The abstract of the 2025 heart-attack trial reports no adverse-event figures. These results concern the full protein, not TB-500. | Controlled trials, full protein only (T1/T2) |
| GHK-Cu | Small topical cosmetic studies. No controlled human data for injected GHK-Cu. | FDA: injected GHK-Cu “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities,” with “limited data in humans.” | Very limited / early human, topical only (T2) |
| CJC-1295 | Two small placebo-controlled studies in healthy adults, 28 and 49 days, of a long-acting version with a half-life of about a week. | The authors reported no serious adverse reactions. The studies measured hormone levels over weeks; they were not designed to find uncommon or long-term effects. FDA’s compounding safety-risk page states that FDA “has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction,” and that “available clinical data are limited.” | Controlled trials, biomarkers only (T1) |
| Ipamorelin | A phase 1 study in 40 healthy men; a phase 2 trial in 114 patients after bowel surgery. | In the phase 2 trial, given intravenously after surgery, adverse events occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group; most patients in both groups had them. FDA’s compounding safety-risk page states that “a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility,” without saying how those events compared with placebo. FDA lists ipamorelin acetate as a substance that may present significant safety risks in outsourcing-facility compounding. | Controlled trial in surgical patients (T1) |
Not listed: other compounds, including KPV and MOTS-c. Absence from this table is not a statement about their safety.
04Which side-effect reports carry the most weight?
Not every report of a side effect carries the same weight. From strongest to weakest:
Events counted in a treated group and a comparison group. The ipamorelin surgery trial shows why the comparison matters: most patients in both groups had adverse events.
Useful for spotting obvious problems; unable to rule out uncommon ones.
A single, well-documented patient. They can raise a signal, and they cannot give a rate.
FDA’s Adverse Event Monitoring System (AEMS, formerly FAERS), the UK Yellow Card scheme, Australia’s TGA reports. The FDA notes there is “no certainty that the reported adverse event was due to the suspect product,” and that it does not receive every report.
Not evidence. We do not use them to describe side effects.
05What don’t we know about peptide side effects?
- Uncommon and long-term effects of any unapproved research peptide. The human studies are too small and too short to see them.
- Whether a reaction came from the molecule or the vial. With unregulated products, contamination or the wrong substance can cause harm that has nothing to do with the named compound.
- How much goes unreported. The FDA notes that compounding pharmacies under section 503A generally do not report adverse events to it.
- Effects of combinations. Evidence attaches to the compound studied. We found no published human study designed to measure the safety of research peptides used together (PubMed, November 2026).
Suspected reaction? Seek medical care first, then report it: FDA MedWatch (US), MHRA Yellow Card (UK) or the TGA (Australia). For anything about your health, a doctor who knows you is the right call.
This content is educational. It is not medical advice and does not describe use in humans. 6AM Wellness products are sold for research use only and are not for human consumption. If you have a health condition, consult a licensed clinician who knows you.